How should gouty arthritis be managed acutely and chronically, including first‑line therapy for an acute flare, indications and dosing for urate‑lowering agents, prophylaxis, and lifestyle modifications?

Gouty Arthritis Management

Acute Gout Flare Treatment

Initiate pharmacologic therapy within 24 hours of symptom onset using NSAIDs, colchicine, or corticosteroids as first-line monotherapy; the choice depends on renal function, cardiovascular risk, gastrointestinal comorbidities, and drug interactions. 1

Treatment Selection Algorithm

Step 1: Assess renal function

• eGFR < 30 mL/min (severe renal impairment or ESRD): Use oral prednisone 30–35 mg daily for 5 days or intra-articular corticosteroid injection for 1–2 accessible joints; avoid NSAIDs and colchicine entirely. 2, 1
• eGFR 30–59 mL/min (moderate renal impairment): Prefer corticosteroids; if colchicine is selected, reduce prophylactic dose to 0.6 mg once daily and monitor closely during acute dosing. 1
• eGFR ≥ 60 mL/min: All three options (NSAIDs, colchicine, corticosteroids) are appropriate. 1

Step 2: Screen for drug interactions

• If patient is taking strong CYP3A4 or P-glycoprotein inhibitors (clarithromycin, erythromycin, cyclosporine, ketoconazole, ritonavir, verapamil): Colchicine is absolutely contraindicated due to fatal toxicity risk; select NSAIDs or corticosteroids. 1, 3

Step 3: Evaluate cardiovascular and gastrointestinal risk

• Heart failure, established cardiovascular disease, active peptic ulcer disease, recent GI bleeding, cirrhosis, or concurrent anticoagulation: Avoid NSAIDs; use corticosteroids or colchicine (if no contraindications). 1, 3

Step 4: Consider timing from symptom onset

• ≤ 12 hours: Colchicine is most effective. 1, 3
• 12–36 hours: Colchicine remains effective; NSAIDs and corticosteroids are equally appropriate. 1, 3
• > 36 hours: Do not use colchicine; select NSAIDs or corticosteroids. 1, 3

Step 5: Assess joint involvement

• Monoarticular or 1–2 large accessible joints (knee, ankle): Intra-articular triamcinolone injection (40 mg for knee, 20–30 mg for ankle) provides targeted control with minimal systemic exposure. 1, 3
• Polyarticular (≥ 4 joints) or multiple large joints: Consider combination therapy (colchicine + NSAID, oral corticosteroid + colchicine, or intra-articular steroid + oral agent); avoid combining systemic NSAID with systemic corticosteroid due to synergistic GI toxicity. 1, 3

Specific Dosing Regimens

Colchicine:

• Acute loading: 1.2 mg orally at first sign of flare, followed 1 hour later by 0.6 mg (total 1.8 mg over 1 hour). 1, 3
• Maintenance: After a 12-hour pause, resume 0.6 mg once or twice daily until the attack completely resolves. 1, 3
• Efficacy: Achieves ≥ 50% pain reduction with number-needed-to-treat of 3–5; causes diarrhea in 23% of patients (versus 77% with obsolete high-dose regimens). 3

NSAIDs:

• Naproxen 500 mg twice daily, indomethacin 50 mg three times daily, or sulindac 200 mg twice daily. 1, 3
• Continue full dose throughout the entire attack until complete resolution; do not taper early. 1, 3
• No single NSAID is superior; selection is based on availability and patient tolerance. 3, 4

Corticosteroids:

• Oral prednisone 30–35 mg daily for 5 days (no taper required), or 0.5 mg/kg/day for 5–10 days followed by abrupt stop or 7–10 day taper. 1, 3
• Intra-articular triamcinolone: 40 mg for knee, 20–30 mg for ankle. 1, 3
• Intramuscular triamcinolone 60 mg single injection for patients unable to take oral medication. 1, 3
• Level A evidence shows oral corticosteroids are equally effective as NSAIDs but with fewer adverse events (27% versus 63%). 3

Critical Pitfalls to Avoid

• Never use colchicine after 36 hours from symptom onset—efficacy drops sharply. 1, 3
• Never combine colchicine with strong CYP3A4/P-gp inhibitors in patients with any renal or hepatic impairment—risk of fatal toxicity. 1, 3
• Never use obsolete high-dose colchicine regimens (0.5 mg every 2 hours)—they cause severe diarrhea in most patients without added benefit. 3, 5
• Never taper NSAIDs early—maintain full dose throughout the attack. 1, 3
• Never combine systemic NSAID with systemic corticosteroid—synergistic GI toxicity. 1, 3

---

Chronic Gout Management: Urate-Lowering Therapy (ULT)

Indications to Initiate ULT

Strong indications (start after first flare):

• Subcutaneous tophi on physical exam or imaging 1, 3
• Radiographic joint damage attributable to gout 1, 3
• Chronic kidney disease stage ≥ 3 1, 3

Conditional indications:

• ≥ 2 gout attacks per year 1, 3, 6
• Past urolithiasis 1
• Serum urate > 9 mg/dL 1, 3
• Patient preference for early intervention 1, 3
• Age < 40 years at disease onset 1, 3

Timing of ULT Initiation

Do not start ULT during an acute flare; wait until the attack has completely resolved. 1, 3

If the patient is already on ULT (allopurinol or febuxostat), continue it without interruption during an acute flare. 1, 3, 2

Allopurinol: First-Line ULT

Initiation and titration protocol:

• Start at 100 mg daily (or 50 mg daily if creatinine clearance 30–50 mL/min). 1, 3
• Increase by 100 mg every 2–4 weeks until serum urate falls below 6 mg/dL. 1, 3
• Typical maintenance dose: 300–600 mg daily; maximum 800 mg daily. 1, 3
• Starting at high doses (e.g., 300 mg) significantly increases risk of acute flares and allopurinol hypersensitivity syndrome. 1, 3

Renal dosing flexibility:

• Allopurinol may be titrated above 300 mg even with renal impairment, provided patients receive education and monitoring for toxicity (pruritus, rash, transaminase elevation). 3

Genetic screening:

• In patients with CKD stage 3 or worse, screen for HLA-B*58:01 allele before starting allopurinol, as this genotype markedly increases risk of fatal hypersensitivity reactions. 3

Serum Urate Targets

• Standard target: < 6 mg/dL for all gout patients, maintained lifelong. 1, 3
• Aggressive target: < 5 mg/dL for severe gout (tophi, chronic arthropathy, frequent attacks) until crystal dissolution. 1, 3
• Avoid maintaining serum urate < 3 mg/dL long-term. 3

Alternative ULT Agents

Febuxostat:

• Indicated when allopurinol at appropriate dose fails to achieve target urate or when allopurinol is intolerable. 3
• Start 40 mg daily and titrate to 80 mg (or 120 mg if needed). 3
• Does not require renal dose adjustment in mild-to-moderate CKD. 3
• Associated with increased all-cause and cardiovascular mortality; not routinely recommended as first-line. 4

Uricosuric agents (probenecid, benzbromarone):

• Appropriate for patients with normal renal function; relatively contraindicated in those with urolithiasis history. 3

Pegloticase:

• Reserved for crystal-proven, severe, debilitating chronic tophaceous gout when all other therapies at maximal doses fail. 3

---

Prophylaxis During ULT Initiation

Provide colchicine 0.6 mg once or twice daily for at least 6 months when starting or adjusting ULT to prevent acute flares triggered by urate mobilization. 1, 3

Duration of Prophylaxis

• Minimum 6 months, or 1, 3
• 3 months after achieving target serum urate < 6 mg/dL if no tophi are present, or 1, 3
• 6 months after achieving target serum urate if tophi are present. 1, 3

Efficacy Evidence

High-quality RCT evidence shows colchicine prophylaxis reduces the proportion of patients experiencing flares during allopurinol initiation from 77% to 33% (p = 0.008). 3

Stopping prophylaxis at 8 weeks leads to doubling of flare rates (from 20% to 40%). 3

Alternative Prophylaxis (When Colchicine Contraindicated)

• Low-dose NSAID plus proton-pump inhibitor (e.g., naproxen 250 mg twice daily with omeprazole 20 mg daily). 3
• Low-dose prednisone < 10 mg/day as second-line prophylaxis. 3, 2
• Maintain alternative prophylaxis for ≥ 6 months during ULT initiation. 3

Renal Impairment Dose Adjustments for Prophylaxis

• CrCl 30–80 mL/min: Reduce colchicine prophylaxis to 0.6 mg once daily. 3
• CrCl < 30 mL/min: Start colchicine at 0.3 mg once daily with close monitoring, or avoid entirely and use alternative prophylaxis. 3, 2

Absolute Contraindications to Colchicine Prophylaxis

• Severe renal impairment (CrCl < 30 mL/min) 3
• Concurrent use of strong CYP3A4 or P-glycoprotein inhibitors (clarithromycin, erythromycin, cyclosporine, ketoconazole, ritonavir, verapamil), especially with any renal or hepatic impairment 3

---

Lifestyle Modifications

Weight loss and regular physical activity lower excess mortality associated with hyperuricemia. 3

Dietary recommendations:

• Limit alcohol (especially beer and spirits), sugar-sweetened beverages, fructose-rich foods, large meals, and excessive meat/seafood. 3, 4
• Encourage low-fat dairy, coffee, and cherries. 3

Medication review:

• Replace loop or thiazide diuretics when possible. 1, 3
• Consider losartan or calcium-channel blockers for hypertension. 3
• Use statins or fenofibrate for hyperlipidemia. 3